FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Lexicon Dropping Zynquista After CRL

[ Price : $8.95]

Lexicon stops development of its diabetes drug Zynquista that received an FDA complete response letter.

Temple Retires; Bumpus Leaves FDA

[ Price : $8.95]

CDER senior advisor for clinical science Bob Temple retires, and FDA principal deputy commissioner Namandj Bumpus leaves the agenc...

Xbrane Refiles Lucentis Biosimilar BLA

[ Price : $8.95]

Xbrane Biopharma refiles a BLA for its investigational ranibizumab, a biosimilar copy of Genentechs age-related macular degenerati...

Alert on AquaFlexFlow Blood Circuits

[ Price : $8.95]

FDA issues a safety alert on Nuwellis AquaFlexFlow UF 500 Plus extracorporeal blood circuit because the device may trigger a weigh...

Senators Introduce Skinny Label Generic Drug Bill

[ Price : $8.95]

Four senators introduce bipartisan legislation to protect generic drug manufacturers from innovator drug lawsuits over skinny labe...

ICH M15 Model-Informed Drug Development Principles

[ Price : $8.95]

FDA publishes an International Council for Harmonization draft M15 guidance on model-informed drug development principles.

AMT Designation Program Guidance

[ Price : $8.95]

FDA publishes a guidance with recommendations for participating in the agencys Advanced Manufacturing Technologies Designation Pro...

ICH E11A Pediatric Extrapolation Guidance

[ Price : $8.95]

FDA publishes the International Council on Harmonization E11A Pediatric Extrapolation guidance.

ICH Clinical Practice Guide Annex

[ Price : $8.95]

FDA publishes Annex 2 of the International Council on Harmonization Good Clinical Practice guidance.

Brands International Limits, Delays Inspection: FDA

[ Price : $8.95]

FDA warns a Canadian Brands International facility about limiting and delaying an inspection that also identified CGMP violations.